Clinical Trials
The trial is a phase II multi-center, randomized-controlled interventional prospective study, and the purpose of this trial is to investigate whether ...
November 22, 2023 | News
Micron has received this grant from the Bill & Melinda Gates Foundation to fund mass production of needle-free vaccines utilizing Micron technology t...
November 20, 2023 | News
A recent clinic trial is expanding the evidence base for the Wobenzym® brand. The results are published in Therapeutic Advances in Musculoske...
November 19, 2023 | News
The availability of DLL4 manufactured under GMP conditions represents a significant milestone for enterprises engaged in developing or manufacturing stem-c...
November 17, 2023 | News
Early results presented at the Union World Conference on Lung Health suggest promise of new compound to fight tuberculosis that will be tested as part of P...
November 17, 2023 | News
CycloSam® is highly synergistic with Telix's existing therapeutic development activity in both prostate cancer and sarcoma. The proposed acquisiti...
November 14, 2023 | News
Medidata, a Dassault Systèmes company, announced that George Clinical, a leading global clinical research organization, is leveraging Medidata's clo...
November 14, 2023 | News
Safety Review Committee evaluated dose level 1 safety data of PMC-403 and approved advancing to the higher dose treatment. The starting dose (0.7m...
November 10, 2023 | News
-Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, today announced new experienc...
November 09, 2023 | News
“The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the Company, our scientists, clinical trial sites, ...
November 09, 2023 | News
Gastric cancer is one of the most common gastrointestinal malignancies in the world, and the number of new cases and deaths of gastric cancer in China...
November 08, 2023 | News
ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations,...
November 08, 2023 | News
Melbourne ophthalmology company PolyActiva is developing a unique biodegradable ocular implant that provides 6 months of sustained drug deli...
November 06, 2023 | News
'GC1109' contains protective antigen (PA) as its active pharmaceutical ingredients produced by recombinant DNA technology which delivers 2 types of protein...
November 06, 2023 | News
Most Read
Bio Jobs
News